Humacyte Inc (HUMA)
6.42
-0.05
(-0.77%)
USD |
NASDAQ |
May 16, 16:00
6.415
0.00 (0.00%)
After-Hours: 20:00
Humacyte Cash from Investing (TTM): 0.588M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 0.588M |
December 31, 2023 | -0.173M |
September 30, 2023 | 5.189M |
June 30, 2023 | 5.471M |
March 31, 2023 | 3.715M |
Date | Value |
---|---|
December 31, 2022 | 4.845M |
September 30, 2022 | -8.412M |
June 30, 2022 | -8.284M |
March 31, 2022 | -8.213M |
December 31, 2021 | -8.22M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-8.412M
Minimum
Sep 2022
5.471M
Maximum
Jun 2023
-1.349M
Average
0.2075M
Median
Cash from Investing (TTM) Benchmarks
Adial Pharmaceuticals Inc | -- |
Gritstone Bio Inc | 93.47M |
Precision BioSciences Inc | 6.524M |
Puma Biotechnology Inc | -20.76M |
Revance Therapeutics Inc | -17.28M |